January 1, 2008Autoimmunity
Anti-heart autoantibodies in familial dilated cardiomyopathy
Key result
Cardiac-specific autoantibodies are found in about 60% of familial and non-familial pedigrees and can serve as biomarkers to predict dilated cardiomyopathy development among healthy relatives.
Population
Patients with familial dilated cardiomyopathy (DCM) and myocarditis, and their relatives
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May warrant family screening in DCM; hypothesis-generating for immunomodulation trials.
Structured PICO
P
Population
Patients with familial dilated cardiomyopathy (DCM) and myocarditis, and their relatives
Cardiac-specific autoantibodies can serve as biomarkers to identify patients with autoimmune myocarditis/DCM who may benefit from immunosuppression or immunomodulation, as well as their at-risk relatives.
Limitations
- Available genetic studies in familial DCM have not accounted for autoimmune phenotype markers, leaving the role of gene defects in autoimmune forms unknown.
Cite This Study
Caforio et al. (2008) conducted a review in Familial dilated cardiomyopathy and myocarditis. Cardiac-specific autoantibodies was evaluated. Cardiac-specific autoantibodies are found in about 60% of familial and non-familial pedigrees and can serve as biomarkers to predict dilated cardiomyopathy development among healthy relatives.